Advanced Enzyme Tech , a global leader in the enzyme and probiotic manufacturing sector, is set to participate in the Pharma and Healthcare conference organized by DAM Capital Advisors Limited on September 23, 2025. The company has submitted its presentation materials to stock exchanges, adhering to regulatory requirements and maintaining transparency with investors.

Company Overview

Advanced Enzyme Tech is a research-driven enterprise with a strong global presence in the manufacturing of enzymes and probiotics. The company serves a diverse range of industries, including human healthcare, animal nutrition, baking, and various processing sectors.

Global Footprint

Advanced Enzyme Tech boasts an impressive operational network, comprising:

• 9 manufacturing units (8 in India, 1 in the USA)
• 7 R&D facilities spread across India, USA, and Germany
• Presence in over 68 countries
• A customer base exceeding 700 clients worldwide

Product Portfolio and Financial Performance

The company maintains a robust portfolio of over 400 products. In its latest financial results, Advanced Enzyme Tech reported:

• Revenue of ₹6,369.00 million
• EBITDA margin of 31.00%

Conference Participation

The investor presentation at the DAM Capital Pharma and Healthcare conference provides Advanced Enzyme Tech an opportunity to showcase its strengths and strategies to potential investors and industry analysts. This platform allows the company to highlight its research capabilities, global reach, and financial performance.

Regulatory Compliance

In line with the Securities and Exchange Board of India (SEBI) regulations, Advanced Enzyme Tech has duly submitted the presentation materials to the stock exchanges. This move underscores the company's commitment to transparency and adherence to regulatory standards.

Advanced Enzyme Tech's participation in this conference reflects its proactive approach to investor relations and its position as a key player in the enzyme and probiotic industry. The event offers a valuable opportunity for the company to engage with the investment community and provide insights into its operations and future prospects.

Advanced Enzyme Tech (AETL), a leading enzyme-focused company, has reported a robust financial performance for the first quarter of FY26. The company's consolidated revenue and profit saw significant year-over-year increases, reflecting strong operational efficiency and market demand for its products.

Financial Highlights

• Consolidated revenue stood at ₹1,859.00 million, up 20% from ₹1,545.00 million in Q1 FY25.
• EBITDA grew 10% to ₹564.00 million.
• Consolidated net profit increased 16% to ₹404.00 million, compared to the same quarter last year.
• EBITDA margin stood at 30.00% and PAT margin at 22.00%.

Segment Performance

Geographical Performance

Operational Performance

The company's performance demonstrates its ability to maintain growth momentum across various sectors. The increase in revenue suggests strong demand for AETL's enzyme products, particularly in human and animal nutrition segments.

Strategic Focus

AETL maintains focus on:

• Expanding its product portfolio in probiotics
• Growing its human nutrition B2C business through the Wellfa brand
• Developing bio-catalysis solutions for API manufacturers

Future Outlook

Advanced Enzyme Tech's strong start to the quarter positions it well for continued success in the enzyme market. The company's focus on innovation and strategic investments in key segments is likely to support its growth trajectory in the coming periods.

Note: All financial figures are in Indian Rupees (INR).